Dr. Martin on Intensive Therapy for Young Patients with MCL
In Partnership With:
Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses standard of care for younger patients with mantle cell lymphoma.
Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses standard of care for younger patients with mantle cell lymphoma (MCL).
In general, there is a consensus that young patients can do well in terms of progression-free survival (PFS) with more intensive approaches, according to Martin. Several physicians are open to the idea of high-dose cytarabine-based induction therapy for younger people who are interested in intensive therapy.
However, many physicians differ in opinions regarding the role and importance of the platinum-based agent, Martin explains. There is an uncertainty regarding the requirement of autologous stem cell transplantation after cytarabine induction. Despite this, the overall agreement among physicians regarding treatment for young patients with MCL is intensive therapy, with data indicating good PFS, according to Martin.
